In the DSM-IV-TR, the term was used to define the features required for a clinical diagnosis of a sexual dysfunction that included deficient or absent sexual fantasies and desire for sexual activity.
To me, this is a litmus test for what this conversation is going to be like. Now we are saying half of the population goes through this thing called menopause. Now we are taking it, I hope, a little more seriously. It will be fascinating if this conversation is fundamentally different this time around. Addyi is a case study for whether things have actually changed.
Pink is a bit of active defiance to me. When people were patting me on the shoulder, saying, ‘Oh the little pink pill,’ I recognized that in that was dismissiveness and trivialization, and that was the very conversation I wanted to have: you perceive [women’s loss of sexual desire] as weakness or unimportant, but I see it very differently. I was criticized for wearing pink and was told people wouldn’t take me seriously. But I believe you always get two choices. You either lean back away from it and distance yourself, or you lean right in toward it. The term was also used in drug studies to determine who is eligible to participate in a study and to track outcomes, like the degree to which the drug works to address the condition.
In 2013, with the publication of the DSM-V, the term was retired and replaced with a new, merged term: “female sexual interest/arousal disorder.” Low libido is one symptom or feature required to qualify for this disorder.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra | 100mg | 60 + 4 Pills | 201.34€ 191.75€ | |
| Cialis Generic | 20mg | 60 + 6 Pills | 117.76€ 112.15€ | |
| Cialis Super Active | 20mg | 60 + 8 Pills | 230.32€ 219.35€ | |
| Kamagra Soft Tabs | 100 mg | 120 + 6 Pills | 311.78€ 296.93€ | |
| Kamagra Soft Tabs | 100 mg | 20 Pills | 79.79€ 75.99€ | |
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ | |
| Viagra Super Active | 100mg | 60 + 8 Pills | 116.84€ 111.28€ | |
| Tadalista Super Active | 20mg | 30 + 6 Pills | 128.09€ 121.99€ | |
| Cialis Generic | 60mg | 90 + 6 Pills | 196.67€ 187.30€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Viagra Soft Tabs | 100mg | 10 Pills | 36.93€ 35.17€ | |
| Cialis Generic | 10mg | 120 + 6 Pills | 178.49€ 169.99€ | |
| Viagra Generic | 200mg | 180 + 10 Pills | 277.56€ 264.34€ |
Q: What are some of the treatment options available for women with HSDD?
We spoke with Stacy Tessler Lindau, MD, MA, a professor in the Department of Obstetrics and Gynecology and an expert in sexual function who runs the University of Chicago Medicine’s Program in Integrative Sexual Medicine and WomanLab.org, to learn more about what this latest pharmaceutical option means for women. Q: When should women talk to their doctor about low sex drive? A: A woman who is bothered or distressed about low sex drive should raise the concern with a doctor. Some women do have lower sex drive than they used to or they would describe themselves as always having lower sex drive than their partner, but they see no problem. In fact, if you are satisfied with the level of your sex drive, then you don’t need a doctor’s help.
Some women have situational low sex drive — meaning they find themselves feeling desire or having sexual thoughts in some situations but they do not feel a desire for or interest in their current partner. They may be struggling with the quality of the relationship or the partner may be unwell. In this situation, the first stop might be to consult a certified sex therapist or couples therapist. Q: When does a low libido qualify as hypoactive sexual desire disorder (HSDD)? A: The term “hypoactive sexual desire disorder” is a technical term used in an important and evolving scientific document called the Diagnostic and Statistical Manual (DSM). A: Treatment options for low libido problems in women depend on the cause of the problem.
It’s an historic first in women’s health. I think this signifies not only scientific recognition of a medical condition that affects millions of women that had been previously discussed only with stigma, not science, but also a cultural recognition that we value sexual health as part of women’s overall wellness, their longevity, and their well-being. And that their sex life doesn’t end at menopause. To me, we played the long game, and culture caught up. I built a male sexual health company at a time when there was only long-acting testosterone treatment for men.
Now there are 26 FDA-approved treatments for some form of male sexual dysfunction, but there were none for women. I watched the big guns not do anything about the science, and that was a commentary on the perspective they had on women’s health: they don’t value sexual health in women the same as they do in men. We left women out of the conversation. And I should have anticipated that the first-ever drug for women’s sexual pleasure would not follow a straight line. To me, it’s about the science. New onset of low libido can be a symptom of an underlying physical or mental health problem. A drop in libido can be related to a life stage or event like pregnancy, post-partum, or grief due to a loss.
Read More: How to Fight Hair Loss During Menopause When Addyi first came out, there were discussions about the risks when taken with alcohol. Studies showed that some women experienced side effects including dizziness, sleepiness and nausea, and less than 2% had to discontinue Addyi because of them. So if you have one or two drinks in the evening, wait a couple of hours before taking Addyi at bedtime. Or if you have more than three drinks, then skip Addyi that night. We [as a society] talk about the risks of Addyi and alcohol in every article.
But it’s not our call, it’s every woman’s call. She gets to weigh the benefits—more desire for sex, more interest in sex, more satisfying sexual events, and less stress over her condition. More women experience sexual dysfunction cost of vardenafil than men globally. The expansion to post-menopausal women is long overdue. As a female founder in health, even when raising money for this product that has a higher prevalence than erectile dysfunction, we weren’t getting any money from Sand Hill Road [a part of Silicon Valley rife with venture capitalists]. A woman might find that her libido is heavily influenced by her partner’s interest in or drive for sex, so an evaluation should include the partner’s health and sexual function.
I always loved pink, and never saw it as a sign of weakness. I see it as a strength to show up exactly as you are. The original version of this story mischaracterized how the drug was approved for post-menopausal women. The FDA required an additional review of data Sprout had already provided; new studies were not conducted. The U.S.
Food and Drug Administration just approved bremelanotide as a new pharmaceutical treatment for pre-menopausal women with low libido. Marketed under the brand name Vyleesi, the injectable medication is used to treat what has been known as hypoactive sexual desire disorder (HSDD). It’s the second libido-enhancing medication women libido pills on the market for women. (The first, Addyi, was approved in 2015 and is a once-a-day pill designed to increase sexual desire.) Statistics vary, but more than a third of women report having low or limited libido and 10 percent have HSDD. Many — but, it’s important to note, not all — are looking for help to increase their sex drive. Certainly, treatments that interfere with sex hormone metabolism like anti-hormone therapies used for breast cancer or infertility or even uterine fibroids
I had built a successful company in men’s sexual health. I had seen what the standard was there. When the same standard wasn’t applied for women, I questioned it and pushed back. I had a six-hour, very public conversation with the FDA about this, and there was a lot of manufactured controversy—because of how we feel about women and sex. The fact is that 50% of the population goes through menopause, and we’re told, “Just relax, take a bubble bath; it’s just a transition period.” It’s literally a biological phenomenon, and we treat it by telling people to just calm down.
There’s a concept in medicine that women’s symptoms are considered more likely to be psychosomatic and more likely based in emotions. It shows up in the way we treat women’s heart attacks, and that it takes longer to prescribe pain medication for women than for men. To me, the basis of that is that we believe women are entirely psychological creatures rooted in emotion, while men are biological creatures. That gives us as a society extraordinary permission to dismiss what women are experiencing, because once we decide that women are emotional, any symptom women report, they’re patted on the shoulder and told to relax. We’ve created a culture of dismissal. can have a very substantial effect on a woman’s libido, as can medicines used to treat mood disorders like depression and anxiety.
Chronic poor quality sleep, including disruption resulting from a baby’s or a partner’s sleep issues, is a common correctable cause of low libido.
Painful sex, often due in part to vaginal dryness, is a common cause of low libido — once the pain is treated, libido often improves.
| Medication Type | Possible Interaction | Risk Level |
|---|---|---|
| Nitroglycerin | Severe hypotension when combined with vasodilators | High |
| Antidepressants | May reduce effectiveness; some ingredients may cause serotonin syndrome | Moderate to high |
| Blood thinners | Increased risk of bleeding with certain herbal components | Moderate |
| Hormonal medications | Possible interference with hormonal balance | Varies |
Vaginal dryness is commonly due to menopause, tightness in the pelvic floor muscles, too much washing in the genital area, lack of sufficient foreplay or sexual arousal, and dermatologic or other medical conditions.
Medicine has understood it for some time now, but what crept in was social commentary, a societal bias that questions whether pleasure matters for women. Read More: What to Know About Early Menopause In the end, Addyi was approved [in 2015 for pre-menopausal women] on the basis of science, with clinical trials involving 13,000 women, which was three times the size of the trials conducted on Viagra at the time of its [FDA] submission. Granted, erectile dysfunction is different from HSDD in women, but the FDA took six months to approve Viagra, and by contrast it took us six years to earn approval for Addyi. Addyi works on neurotransmitters in the brain. If you think of other drugs that work in the central nervous system, we don’t separate populations by age in the same way.
It’s the same molecule, and the same dosage as Addyi that was approved for HSDD. But there is a pattern in women’s health where we lead with a skewed point of view on the importance of factors—including the desire for sex—that are societally conditioned. The world wasn’t ready for a female Viagra. Not only do we rule out anything a woman is experiencing as probably emotional and not medical, if there is a medical solution, we lead with its risk. The reason for that is that we have already dismissed that there is any benefit in addressing her symptoms. Treatment depends on the cause and the cause is often multifactorial.